The European Association for the Study of Diabetes 2017 annual meeting will take place in Lisbon, Portugal from September 11-15, 2017. Some interesting research on Type 1 diabetes is on tap for the meeting, so here's a sneak preview!
Do you tend to bolus for your meal or snack during or after eating? If so, you may be unwittingly getting in your own way.
Although it didn't work wonders for blood glucose (BG) levels, liraglutide improved anthropometric and metabolic parameters without causing an increase in hypoglycemia, according to the results of a clinical trial published in July in Diabetes, Obesity, and Metabolism.
Have you ever noticed when you look at your lab results, there's a measure of kidney function called eGFR that is reported for both non-African American, and for African American? That's because there are racial and ethnic differences in kidney function decline. When it comes to A1c levels, they are higher in black people than in white people. It is debatable if this is because of poorer glycemic control, or whether there are, in fact, differences between the races in the glycation of hemoglobin.
Sotagliflozin is a drug in development, under investigation by Lexicon Pharmaceuticals and Sanofi. It is a first-in-class, oral dual inhibitor of sodium-glucose cotransporter types 1 and 2 (SGLT1 and SGLT2).
New research shows promise in keeping beta cell insulin production stable in those with newly diagnosed type 1 diabetes.
Answer our type 1 diabetes trivia question and win a free book!
We'd like to know what you think! Participate in our Integrated Diabetes Services monthly survey.
Wouldn't it be great if a commercially-available product existed that was derived from stem cells and could effectively replace pancreatic islet cells to allow folks who can't produce endogenous insulin to actually start making it? ViaCyte is working on turning this into a reality someday.
According to research presented at the annual meeting of the American Diabetes Association (ADA) in June, a new glucagon product is much easier to use than is the traditional formulation for injection. Could this mean that it's more likely that a caregiver would be willing to administer it when needed?
Half unit dosing with Humalog is about to become a little more convenient for insulin pen users!
Could a generic drug with over 100 years of clinical use and safety data eventually prove to be the key to reversing Type 1 diabetes?
Ascensia Diabetes Care announced on June 8 that it signed a development agreement with Insulet Corporation, which you probably know better as the company that makes Omnipod insulin pumps.
Drivers with Type 1 diabetes have a higher risk of motor vehicle collisions, as compared to their spouses without diabetes. Are you doing all you can to be a safe driver?